tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Earache D004433 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cheilitis D002613 2 associated lipids
Tongue Diseases D014060 2 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Nail Diseases D009260 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Venous Insufficiency D014689 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Telangiectasis D013684 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Vitiligo D014820 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Pruritus Ani D011538 2 associated lipids
Deglutition Disorders D003680 2 associated lipids
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Paresis D010291 2 associated lipids
Myxedema D009230 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Angiofibroma D018322 2 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Mediastinitis D008480 2 associated lipids
Oliguria D009846 2 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Fibroadenoma D018226 2 associated lipids
Mucinoses D017520 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Labyrinthitis D007762 2 associated lipids
Paraproteinemias D010265 2 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Fungemia D016469 2 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Pharyngitis D010612 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Leg Injuries D007869 2 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Yamamoto K et al. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. 1990 Immunology pmid:1689694
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kang Y et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. 1990 Transplant. Proc. pmid:1689889
Jain AB et al. FK 506 dosage in human organ transplantation. 1990 Transplant. Proc. pmid:1689890
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
McCauley J et al. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. 1990 Lancet pmid:1690326
Hoffman AL et al. The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. 1990 Transplantation pmid:1690469
Woo J et al. The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. 1990 Scand. J. Immunol. pmid:1690915
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Morimoto T et al. Pancreaticoduodenal allotransplantation with FK 506 in the dog. 1990 Transplant. Proc. pmid:1691550
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Thomson AW FK-506 enters the clinic. 1990 Immunol. Today pmid:1692221
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Deguchi K et al. [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. 1990 No To Shinkei pmid:1697182
Murase N et al. Prevention of spontaneous diabetes in BB rats with FK 506. 1990 Lancet pmid:1697397
Justice RM et al. The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. 1990 Biochem. Biophys. Res. Commun. pmid:1697463
Todo S et al. Liver, kidney, and thoracic organ transplantation under FK 506. 1990 Ann. Surg. pmid:1697743
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia. 1990 Life Sci. pmid:1698241
Kurasawa K et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. 1990 Clin. Immunol. Immunopathol. pmid:1698584
Miyagawa J et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. 1990 Diabetologia pmid:1698679
Isai H et al. FK 506 and orthotopic liver transplantation in the rat. 1990 Transplant. Proc. pmid:1699329
Suzuki S et al. In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506. 1990 Heart Vessels pmid:1699922
Bierer BE et al. Probing immunosuppressant action with a nonnatural immunophilin ligand. 1990 Science pmid:1700475
Woo J et al. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. 1990 Immunology pmid:1703987
Fung JJ et al. Overview of FK506 in transplantation. 1990 Clin Transpl pmid:1715740
Pugh-Humphreys RG et al. The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. 1990 Immunology pmid:1696242
Mochizuki M and Kawashima H Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. 1990 Autoimmunity pmid:1717007
Ni M et al. FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. 1990 Autoimmunity pmid:1717008
Collier SJ Immunosuppressive drugs. 1989-1990 Curr. Opin. Immunol. pmid:2484794
McCauley J et al. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. 1989 Dec 23-30 Lancet pmid:2481200
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. 1989 Transplantation pmid:2465592
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. 1989 Transplantation pmid:2465593
Takabayashi K et al. Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. 1989 Clin. Immunol. Immunopathol. pmid:2466594
Morris RE et al. Immunopharmacology of FK-506. 1989 Transplant. Proc. pmid:2468201
Yoshimura N et al. A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. 1989 Transplant. Proc. pmid:2468202
Thomson AW et al. Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. 1989 Transplant. Proc. pmid:2468203
Sanghvi A et al. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. 1989 Transplant. Proc. pmid:2468204
Takagishi K et al. Effects of FK-506 on collagen arthritis in mice. 1989 Transplant. Proc. pmid:2468205
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Morimoto T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. 1989 Transplant. Proc. pmid:2468207
Tsuchimoto S et al. Orthotopic liver transplantation in rats receiving FK506. 1989 Transplant. Proc. pmid:2468208
Yokota K et al. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. 1989 Transplant. Proc. pmid:2468209
Inagaki K et al. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. 1989 Transplant. Proc. pmid:2468210
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Watanabe K et al. Prolongation effect of a small dose of FK506, cyclosporine, or azathioprine on renal allografts in dogs treated with fractionated lymphoid irradiation and donor bone marrow cell infusion. 1989 Transplant. Proc. pmid:2468213
Sakamoto K et al. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. 1989 Transplant. Proc. pmid:2468222
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Ochiai T et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. 1989 Transplant. Proc. pmid:2468228
Yasunami Y et al. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. 1989 Transplant. Proc. pmid:2468234
Kobayashi C et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. 1989 Transplant. Proc. pmid:2468254
Kuroki H et al. Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis. 1989 Transplant. Proc. pmid:2468255
Arai K et al. Prolonged limb allograft survival with short-term treatment with FK-506 in rats. 1989 Transplant. Proc. pmid:2468256
Ishibashi M et al. Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. 1989 Transplant. Proc. pmid:2469228
Starzl TE et al. Liver transplantation: an unfinished product. 1989 Transplant. Proc. pmid:2469232
Hatanaka H et al. FK-506 related compounds produced by Streptomyces tsukubaensis No. 9993. 1989 J. Antibiot. pmid:2470720
Gschwendt M et al. The immunosuppressant FK-506, like cyclosporins and didemnin B, inhibits calmodulin-dependent phosphorylation of the elongation factor 2 in vitro and biological effects of the phorbol ester TPA on mouse skin in vivo. 1989 Immunobiology pmid:2471685
Fujii Y et al. Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. 1989 Transplantation pmid:2472025
Tocci MJ et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. 1989 J. Immunol. pmid:2472451
Beck Y and Akiyama N Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro. 1989 Transplant. Proc. pmid:2472695
Thomson AW FK-506--how much potential? 1989 Immunol. Today pmid:2473767
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Ochiai T et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. 1989 Transplantation pmid:2474209
Siekierka JJ et al. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. 1989 J. Immunol. pmid:2474605
Thomson AW and Woo J Immunosuppressive properties of FK-506 and rapamycin. 1989 Lancet pmid:2474733
Todo S et al. Renal transplantation in baboons under FK 506. 1989 Surgery pmid:2474865
Kay JE et al. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. 1989 Immunology pmid:2475433
Moriyama S [Experimental tracheal reconstruction by allotransplantation]. 1989 Nihon Kyobu Geka Gakkai Zasshi pmid:2475555
Freedman RB Immunosuppression. Convergence of drug action. 1989 Nature pmid:2477712
Siekierka JJ et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. 1989 Nature pmid:2477714
Harding MW et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. 1989 Nature pmid:2477715
Kay JE et al. The mechanism of action of the immunosuppressive drug FK-506. 1989 Cell. Immunol. pmid:2478301
Starzl TE et al. FK 506 for liver, kidney, and pancreas transplantation. 1989 Lancet pmid:2478846
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130
Francavilla A et al. Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. 1989 Lancet pmid:2479802
Walliser P et al. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. 1989 Immunology pmid:2480331
Aoki M et al. [Histological observations of immunosuppressive effects of FK-506 in canine lung allotransplantation]. 1989 Bull Chest Dis Res Inst Kyoto Univ pmid:2482787
Kay JE and Benzie CR T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506. 1989 Immunol. Lett. pmid:2483716
Leonard DK et al. Toxicity of FK-506 in human fetal pancreas. 1989 Diabetes pmid:2463195
Stephen M et al. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. 1989 Transplantation pmid:2463701
Inamura N et al. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. 1988 Clin. Immunol. Immunopathol. pmid:2446810
Inamura N et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. 1988 Transplantation pmid:2447690
Ochiai T et al. Studies on FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450414
Immunosuppression: FK506. 1988 Transplant. Proc. pmid:2450415
Todo S et al. Effect of FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450416
Tsuchimoto S et al. [Orthotopic liver transplantation in the rat--immunosuppressive effect of FR100906 on the survival of liver allografts]. 1988 Nihon Geka Gakkai Zasshi pmid:2452341
Nakajima K et al. Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. 1988 Transplantation pmid:2454521
Todo S et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. 1988 Surgery pmid:2456627
Kawashima H et al. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. 1988 Invest. Ophthalmol. Vis. Sci. pmid:2458329
Warty V et al. FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. 1988 Transplantation pmid:2458643
Hewitt CW and Black KS Comparative studies of FK506 with cyclosporine. 1988 Transplantation pmid:2458644
Woo J et al. Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. 1988 Immunology pmid:2460401
Hatanaka H et al. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics. 1988 J. Antibiot. pmid:2461926
Inamura N et al. Immunosuppressive effect of FK506 on experimental allergic encephalomyelitis in rats. 1988 Int. J. Immunopharmacol. pmid:2463974
Hatanaka H et al. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. I. Taxonomy of the producing strain. 1988 J. Antibiot. pmid:3198493